Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss of $0.12, Beat on Revenues

Sensus Healthcare, Inc. (NASDAQ: SRTS) reported Q1 EPS of ($0.12). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $4.3 million.

Highlights of the first quarter of 2017 and recent weeks include (all comparisons are with the first quarter of 2016, unless otherwise noted):

• Revenues of $4.4 million, up 43.5% compared with $3.0 million
• Gross margin of 65.6%, up from 63.7%
• Increased sales organization headcount to 20 versus 17 as of December 31, 2016
• Shipped 14 systems including seven SRT-100 Vision™ systems, bringing the worldwide installed base to 284 units; 66 units are being used to treat keloid scars
• Installed a second SRT-100 Vision system in Israel
• Submitted an application for SRT-100 clearance in Mexico
• Presentations made by Key Opinion Leaders at the American Academy of Dermatology (AAD) Annual Meeting on the use of superficial radiation therapy
• Participated in the annual South Beach Symposium Industry CEO Forum to discuss "The Future of Innovation in Dermatology and Aesthetics in an Era of Healthcare Upheaval

For earnings history and earnings-related data on Sensus Healthcare, Inc. (SRTS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Sensus Healthcare, Inc. (SRTS) Misses Q2 EPS by 41c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery